191 related articles for article (PubMed ID: 12622629)
1. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis.
Sampogna F; Sera F; Mazzotti E; Pasquini P; Picardi A; Abeni D;
Arch Dermatol; 2003 Mar; 139(3):353-8; discussion 357. PubMed ID: 12622629
[TBL] [Abstract][Full Text] [Related]
2. The self-administered psoriasis area and severity index is valid and reliable.
Feldman SR; Fleischer AB; Reboussin DM; Rapp SR; Exum ML; Clark AR; Nurre L
J Invest Dermatol; 1996 Jan; 106(1):183-6. PubMed ID: 8592072
[TBL] [Abstract][Full Text] [Related]
3. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).
Koek MB; Buskens E; van Weelden H; Steegmans PH; Bruijnzeel-Koomen CA; Sigurdsson V
BMJ; 2009 May; 338():b1542. PubMed ID: 19423623
[TBL] [Abstract][Full Text] [Related]
4. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial.
Fleischer AB; Feldman SR; Dekle CL
J Dermatol; 1999 Apr; 26(4):210-5. PubMed ID: 10343464
[TBL] [Abstract][Full Text] [Related]
5. Influence of psoriasis lesions' location and severity on psychosocial disability and psychopathology. Observational study and psychometric validation of the SAPASI Portuguese version.
Teixeira A; Ribeiro C; Gaio R; Torres T; Magina S; Pereira T; Teixeira M; Rocha JC; Lobo JMS; Almeida IF; Vidal DG; Pedrosa E Sousa HF; Dinis MAP; Almeida V
J Psychosom Res; 2022 Mar; 154():110714. PubMed ID: 35007943
[TBL] [Abstract][Full Text] [Related]
6. Translation and Validation of the Self-Assessment Psoriasis Area Severity Index.
Laskowski M; Schiöler L; Wennberg AM; Torén K; Gustafsson H
Dermatology; 2023; 239(5):794-801. PubMed ID: 36907178
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of symptoms experienced by patients with different clinical types of psoriasis.
Sampogna F; Gisondi P; Melchi CF; Amerio P; Girolomoni G; Abeni D;
Br J Dermatol; 2004 Sep; 151(3):594-9. PubMed ID: 15377345
[TBL] [Abstract][Full Text] [Related]
8. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
[TBL] [Abstract][Full Text] [Related]
9. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis.
Sampogna F; Sera F; Abeni D;
J Invest Dermatol; 2004 Mar; 122(3):602-7. PubMed ID: 15086541
[TBL] [Abstract][Full Text] [Related]
10. Self-reported psoriasis severity and quality of life assessment at Comano spa.
Pagliarello C; Calza A; Di Pietro C; Tabolli S
Eur J Dermatol; 2012; 22(1):111-6. PubMed ID: 22063458
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.
Mazzotti E; Picardi A; Sampogna F; Sera F; Pasquini P; Abeni D;
Br J Dermatol; 2003 Aug; 149(2):318-22. PubMed ID: 12932238
[TBL] [Abstract][Full Text] [Related]
12. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis.
Henseler T; Schmitt-Rau K
Int J Dermatol; 2008 Oct; 47(10):1019-23. PubMed ID: 18986347
[TBL] [Abstract][Full Text] [Related]
13. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis.
Sampogna F; Chren MM; Melchi CF; Pasquini P; Tabolli S; Abeni D;
Br J Dermatol; 2006 Feb; 154(2):325-31. PubMed ID: 16433804
[TBL] [Abstract][Full Text] [Related]
14. Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study.
Tabolli S; Sampogna F; di Pietro C; Mannooranparampil TJ; Ribuffo M; Abeni D
Am J Clin Dermatol; 2013 Apr; 14(2):139-45. PubMed ID: 23413102
[TBL] [Abstract][Full Text] [Related]
15. Inter-observer reliability of the PASI in a clinical setting.
Cabrera S; Chinniah N; Lock N; Cains GD; Woods J
Australas J Dermatol; 2015 May; 56(2):100-2. PubMed ID: 25753553
[TBL] [Abstract][Full Text] [Related]
16. Physical and psychologic measures are necessary to assess overall psoriasis severity.
Kirby B; Richards HL; Woo P; Hindle E; Main CJ; Griffiths CE
J Am Acad Dermatol; 2001 Jul; 45(1):72-6. PubMed ID: 11423838
[TBL] [Abstract][Full Text] [Related]
17. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.
Armstrong AW; Parsi K; Schupp CW; Mease PJ; Duffin KC
JAMA Dermatol; 2013 May; 149(5):577-82. PubMed ID: 23426158
[TBL] [Abstract][Full Text] [Related]
18. Severity and management of psoriasis within primary care.
Wade AG; Crawford GM; Young D; Leman J; Pumford N
BMC Fam Pract; 2016 Oct; 17(1):145. PubMed ID: 27737638
[TBL] [Abstract][Full Text] [Related]
19. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial.
Fleischer AB; Clark AR; Rapp SR; Reboussin DM; Feldman SR
J Invest Dermatol; 1997 Aug; 109(2):170-4. PubMed ID: 9242503
[TBL] [Abstract][Full Text] [Related]
20. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Bożek A; Reich A
Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
